Compare SPRO & GEOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | GEOS |
|---|---|---|
| Founded | 2013 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.5M | 134.5M |
| IPO Year | 2017 | 1997 |
| Metric | SPRO | GEOS |
|---|---|---|
| Price | $2.79 | $8.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 663.0K | 243.9K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $66,802,000.00 | ★ $110,803,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $300.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $1.80 | $5.86 |
| 52 Week High | $3.09 | $29.89 |
| Indicator | SPRO | GEOS |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 43.31 |
| Support Level | $2.18 | $7.45 |
| Resistance Level | $2.90 | $8.85 |
| Average True Range (ATR) | 0.17 | 0.59 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 58.45 | 39.31 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Geospace Technologies Corp is engaged in designing and manufacturing sophisticated technology solutions for applications in smart water management, energy exploration, as well as industrial and Internet of Things. Its seismic equipment is used to locate, characterize, and monitor hydrocarbon reservoirs and is also marketed for vibration monitoring, security, and geotechnical uses. The company also produces non-seismic products such as Hydroconn cables, imaging equipment, remote shutoff water valves, and IoT platforms, and provides contract manufacturing services. The company's business segments includes Smart Water, Energy Solutions and Intelligent Industrial. The majority of its revenue is generated from the Energy Solutions segment.